Alexion Pharmaceuticals Inc ALXN:NASDAQ

Earnings Announcement Next Earnings date is expected on 10/29/2020
Last Price$121.61NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/23/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$121.62 (1)
Ask (Size)$122.20 (11)
Day Low / HighN/A - N/A
Volume996.8 K

View Biotechnology IndustryPeer Comparison as of 10/23/2020


Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $121.61
Change: +1.94 (1.62%)
Volume: 996.8 K
4:00PM ET 10/23/2020

Moderna Inc ( NASDAQ )

Price: $70.53
Change: -0.31 (0.44%)
Volume: 3.7 M
4:00PM ET 10/23/2020

Immunomedics Inc ( NASDAQ )

Price: $87.86
Change: 0.00 (0.00%)
Volume: 15.3 M
4:00PM ET 10/22/2020

Incyte Corp ( NASDAQ )

Price: $89.69
Change: -0.80 (0.88%)
Volume: 652.0 K
4:00PM ET 10/23/2020

Seagen Inc ( NASDAQ )

Price: $196.92
Change: -3.74 (1.86%)
Volume: 479.6 K
4:15PM ET 10/23/2020

Read more news Recent News

Correction: Earnings Estimate Changes and Stock Price Data
5:59PM ET 10/18/2020 MT Newswires

On October 16-18, an outside data vendor for MT Newswires published incorrect earnings estimate changes and last stock price information for several...

Alexion Pharmaceuticals' Q3, 2020 and 2021 Earnings Estimates Scaled Up
3:55AM ET 10/17/2020 MT Newswires

Alexion Pharmaceuticals Inc's (NASDAQ:ALXN, Recent Price: 164.45) earnings targets for Q3 ending September 30, 2020, and the forecasts for 2020 and 2021...

Analyst Actions: Morgan Stanley Adjusts Price Target on Alexion Pharmaceuticals to $121 From $120, Keeps Equal-Weight Rating
9:55AM ET 10/13/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) has an average rating of outperform and price targets ranging from $117 to $175, according to analysts polled by Capital IQ....

Alexion Pharmaceuticals Wins FDA Approval For New Formulation of Blood Disorder Drug Ultomiris
9:32AM ET 10/12/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) said Monday the US Food and Drug Administration has approved the 100 mg/mL new formulation of Ultomiris for the treatment of...

View all Commentary and Analysis

Plenty More Upside To See In Alexion Pharmaceuticals In 2020
11:07AM ET 10/21/2020 Seeking Alpha

ClearBridge Sustainability Leaders Strategy Portfolio Manager Commentary Q3 2020
1:30PM ET 10/19/2020 Seeking Alpha

Argenx: Competitive Positioning In The GMG Space
5:15AM ET 10/13/2020 Seeking Alpha

Wall Street Breakfast: The Week Ahead
10:16AM ET 10/11/2020 Seeking Alpha

Company Profile

Business DescriptionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. View company web site for more details
Address121 Seaport Boulevard
Boston, Massachusetts 02210
Number of Employees2,656
Recent SEC Filing10/01/20208-K
Chief Executive Officer & DirectorLudwig N. Hantson
President & DirectorAradhana Sarin
Chief Commercial, Global Operations Officer & EVPBrian M. Goff
Chief Information Officer & Senior Vice PresidentGeorge Llado

Company Highlights

Price Open$120.48
Previous Close$119.67
52 Week Range$72.67 - 128.57
Market Capitalization$26.7 B
Shares Outstanding219.2 M
SectorHealth Technology
Next Earnings Announcement10/29/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings33.19
Earnings per Share$10.41
Beta vs. S&P 500N/A
Revenue$4.1 B
Net Profit Margin15.40%
Return on Equity7.71%

Analyst Ratings as of 10/06/2020

Consensus RecommendationConsensus Icon
Powered by Factset